Wasif Qureshi, MD
Cardiovascular Disease · Bear, DENPI 1861619975
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $81,573 of the $121,910 with a category attached, or 66.9%. Novo Nordisk accounts for 63.7% of it on its own, with 41 other manufacturers making up the rest. 2025 is the largest year on record at $86,251, 7.7 times the $11,263 reported in 2019. Among cardiovascular disease clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 471 payments — averaging $258.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$78K
- Boston Scientific$21K
- Abbott$16K
- Edwards Lifesciences$1K
- Amgen$732
- Medtronic$679
- plus $4K from 36 others
Across 5 payments — averaging $2195.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$11K
What the payments were for
- Consulting fees$18,29815%
- Speaking & faculty fees$81,57367%
- Travel & lodging$9,6318%
- Food & beverage$12,26210%
- Education$1470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$77,247
- Watchman$12,000
- AMPLATZER AMULET$9,474
- WATCHMAN Access System$8,147
- MitraClip$2,008
- TRICLIP$1,464
- EVOQUE$675
- AMPLATZER$228
- Edwards SAPIEN 3 Transcatheter Heart Valve$218
- ENSITE$189
- WATCHMAN FLX$150
- LifeVest$139
- COREVALVE EVOLUT R$134
- CoreValve Evolut$122
- GENERAL - STRUCTURAL HEART$107
- Confirm Rx$100
How this compares
$121,910 in reported general payments places this provider in the 95th percentile of 104 cardiovascular disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 424 | $483,123 |
| XareltoRivaroxaban | 152 | $200,159 |
| EntrestoSacubitril/Valsartan | 141 | $174,600 |
| Repatha SureclickEvolocumab | 117 | $146,325 |
| BrilintaTicagrelor | 89 | $91,626 |
| JardianceEmpagliflozin | 86 | $81,313 |
| FarxigaDapagliflozin Propanediol | 24 | $38,455 |
| Praluent PenAlirocumab | 33 | $30,891 |
| MultaqDronedarone Hcl | 19 | $25,373 |
| Atorvastatin Calcium | 1,037 | $17,359 |
| NexlizetBempedoic Acid/Ezetimibe | 15 | $15,342 |
| OzempicSemaglutide | 13 | $11,949 |
| Rosuvastatin Calcium | 399 | $9,030 |
| Ranolazine ErRanolazine | 118 | $8,153 |
| ClopidogrelClopidogrel Bisulfate | 640 | $8,038 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $316 | $483,123424 claims |
| Johnson & JohnsonXarelto | $295 | $200,159152 claims |
| NovartisEntresto | $493 | $174,600141 claims |
| AstraZenecaBrilinta, Farxiga | $525 | $130,081113 claims |
| Boehringer IngelheimJardiance | $220 | $81,31386 claims |
| Sanofi-aventis U.S. LLCMultaq | $152 | $25,37319 claims |
| Esperion Therapeutics, Inc.Nexlizet | $226 | $15,34215 claims |
| Novo NordiskOzempic | $77,612 | $11,94913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 104 cardiovascular disease providers in Delaware.
Other cardiovascular disease in Bear
- Mark ZwebenBear$2K
- Vinay HosmaneWilmington$256K
- Rajinder PrasadLewes$72K
- Ehtasham QureshiLewes$52K
- Edward GoldenbergNewark$52K
- Muhammad ShakirNewark$47K
- Anthony AlfieriNewark$45K
- Sean DikdanNewark$42K
- Kirk GarrattNewark$38K
- Anthony ClayNewark$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.